KY-1044  (Synonyms: Alomfilimab; SAR 445256)

KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

ICOS/CD278

KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 hours) causes human natural killer (NK) cells expressing hICOS (5:1 effector:target cell ratio) to induce potent ADCC-mediated killing (EC₅₀=5.6 pmol/L)^[1].
KY-1044 significantly induces the luciferase signal (EC₅₀ of 0.15 nmol/L). A similar EC₅₀ is obtained against mouse ICOS (0.53 nmol/L), rat ICOS (0.48 nmol/L), or cynomolgus monkey ICOS (0.22 nmol/L)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; ip; twice a week for 3 weeks) mIgG2a (effector enable) monotherapy blocks tumor growth in lymphoma/myeloma tumor models^[1].
In syngeneic mouse tumor models, KY-1044 depletes ICOS^high Treg and increases the intratumoral T_Eff:Treg ratio, resulting in increased secretion of IFNγ and TNFα by T_Eff cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29851  [NCBI]

Q9Y6W8

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.5 kDa

2489390-15-8

Liquid

Colorless to light yellow

[KY-1044]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized ICOS Protein, Human can bind Alomfilimab. The EC₅₀ for this effect is 11.35 ng/mL.
• 
  Flow Cytometry analysis of Jurkat cells labelling ICOS/CD278 (red) with KY-1044 (anti-ICOS/CD278) (HY-P99431). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001).

• [1]. Richard C.A. Sainson, et al. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer Immunol Res. 2020 Dec;8(12):1568-1582.  [Content Brief]